Andere Sprachen Evelo Biosciences, Inc.

Aktien

A3EJMP

US2997342025

EVLO

Verzögert OTC Markets Andere Börsenplätze 19:05:39 29.04.2024			% 5 Tage	% 1. Jan.
0,0419 ^USD	-15,35 %		-3,90 %	-31,87 %

2023	Evelo Biosciences, Inc. gibt bekannt, dass Simba Gill als Chief Executive Officer ausscheidet	CI
2023	Evelo Biosciences, Inc. kündigt Änderungen in der Geschäftsführung mit Wirkung zum 1. Dezember 2023 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : More Tech -2-	25.04.
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11.04.
North American Morning Briefing : Focus Turns to -2-	04.04.
North American Morning Briefing : Stocks Set for -2-	28.03.
North American Morning Briefing : Investors -2-	21.03.
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	14.12.
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	11.12.
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	11.12.
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	21.11.
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	21.11.
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	21.11.
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Sector Update: Health Care Stocks Retreat in Late Afternoon	17.10.23
Sector Update: Health Care	17.10.23
Top Midday Decliners	17.10.23
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17.10.23
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	17.10.23
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17.10.23
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17.10.23
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	10.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Evelo Biosciences, Inc.

Aktien

A3EJMP

US2997342025

EVLO

Andere Sprachen

Filter